MembershipPractice ManagementAdvocacyPublicationsEducation & CareersFoundation

HOME > PRACTICE MANAGEMENT > CLINICAL SUPPORT > QUALITY Drug Safety - Table 2

Clinical SupportAffiliate Society CouncilBibliography of Criteria, Guidelines, and Health Status AssessmentsClassification and Response CriteriaHealth Status AssessmentsDisease Activity Indexes and Damage IndexesPractice GuidelinesPosition StatementsClinician ResearchersRheumatology Clinical RegistryQualityDrug SafetyStandards of Practice for Rheumatology Health ProfessionalsPatient ResourcesOffice SupportPatient DocumentationCodingMedicarePQRIHealth Information TechnologyInsuranceLegal & ComplianceBenchmarking SurveysFive ThingsQuick Links for Managing Your PracticeCurrent Issues in Practice Management

Drug Safety - Table 2

Return to Quality Home

Table 2. Laboratory monitoring for established disease modifying anti-rheumatic drugs (Frequency in Weeks)*

DRUG	Hemoglobin or Hematocrit	WBC	Platelet Count	Serum Creatinine	AST or ALT	Albumin	Urinary Protein	Other
Hydroxychloroquine								Fundoscopic exam and visual fields annually
Sulfasalazine	12	12	12
Methotrexate	8	8	8	8	8	8
Leflunomide	8	8	8	8	8	8
Azathioprine	12	12	12
Intramuscular Gold	8	8	8				8
Oral Gold	12	12	12				12
Cyclosporine				4
Glucocorticoids								Urine or blood glucose annually

*WBC = white blood cell count; AST = aspartate aminotransferase; ALT = alanine aminotransferas

Back to Drug Safety QPI